Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Aug 29, 2024 8:05am EDT

Rigel to Participate in Upcoming September Investor Conferences

Aug 06, 2024 4:01pm EDT

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 30, 2024 8:05am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

Jun 25, 2024 8:00am EDT

Rigel Announces Reverse Stock Split

Jun 24, 2024 4:05pm EDT

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

Jun 14, 2024 3:05am EDT

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Jun 03, 2024 8:13am EDT

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

May 30, 2024 8:05am EDT

Rigel to Present at the Jefferies Global Healthcare Conference

May 23, 2024 5:00pm EDT

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 07, 2024 4:01pm EDT

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …41
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin